<DOC>
	<DOC>NCT02798913</DOC>
	<brief_summary>The objective of the present study was to evaluate the prognostic impact of prolonged dual antiplatelet therapy (DAPT) with acetylsalicylic acid plus clopidogrel on the incidence of major adverse cardiovascular events and major adverse limb events after percutaneous lower extremity revascularization in patients with lower extremity peripheral arterial disease (LE-PAD).</brief_summary>
	<brief_title>Effects of Prolonged DAPT After Lower Extremity Percutaneous Transluminal Angioplasty (PTA) in Patients With LE-PAD</brief_title>
	<detailed_description />
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<criteria>LEPAD at stage 2 of Fontaine's classification (intermittent claudication) successful PTA of aortoiliac, femoropopliteal ore belowtheknee segments critical limb ischemia recent acute coronary syndrome (&lt; 12 months) recent cerebrovascular event (&lt; 12 months) recent myocardial, carotid or peripheral revascularization (&lt; 12 months) recent history of bleeding (&lt; 12 months) other indication for clopidogrel therapy indication for anticoagulation decompensated heart failure malignant neoplasm</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>dual antiplatelet therapy</keyword>
	<keyword>peripheral transluminal angioplasty</keyword>
</DOC>